BRD4 and chronic myelogenous leukemia, BCR-ABL1 positive: In line with this concept, the BRD4/MYC-targeting drug JQ1 inhibits the IFN-G-induced expression of PD-L1 on LSC in patients with AML and CML (Figure 2) [61].